Australia markets closed

Ultragenyx Pharmaceutical Inc. (RARE)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
80.00-1.00 (-1.23%)
At close: 4:00PM EDT
80.00 0.00 (0.00%)
After hours: 04:13PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close81.00
Open81.14
Bid79.88 x 900
Ask108.00 x 1800
Day's range79.68 - 82.66
52-week range76.78 - 179.65
Volume359,439
Avg. volume413,069
Market cap5.427B
Beta (5Y monthly)1.82
PE ratio (TTM)N/A
EPS (TTM)-5.40
Earnings date25 Oct 2021 - 29 Oct 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est139.74
  • Zacks

    Ultragenyx (RARE) Begins Angelman Syndrome Study in Canada

    Ultragenyx (RARE) and GeneTx Biotherapeutics dose the first patient in a phase I/II study on GTX-102 for treating patients with Angelman syndrome in Canada.

  • GlobeNewswire

    GeneTx and Ultragenyx Announce First Patient Dosed in Canada in Phase 1/2 Clinical Trial of GTX-102 in Patients with Angelman Syndrome

    SARASOTA, Fla. and NOVATO, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- GeneTx Biotherapeutics LLC and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), companies partnered in the development of GTX-102, an investigational treatment for Angelman syndrome, today announced that the first patient has been dosed in the Phase 1/2 study in Canada with three other patients enrolled and scheduled to begin dosing. “We have been actively working with our principal investigators across all three regions over the

  • GlobeNewswire

    Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    NOVATO, Calif., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of non-qualified stock options to purchase an aggregate of 8,620 shares of common stock of the company and 2,880 restricted stock units of the company’s common stock to one newly hired non-executive officer employee of the company. The award was ap